Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02953782 | Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 78 | Gilead SciencesINDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT04761744 | A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers | unknown | Phase 2 | 48 | Korean Cancer Study GroupOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01670097 | Dexamethasone Dyspnea Study | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT01554371 | Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 44 | University of California, San FranciscoOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | terminated | Phase 1 / Phase 2 | 7 | Oncovir, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02587962 | Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors | terminated | Phase 1 / Phase 2 | 34 | MedivirINDUSTRY | 1 | Jan 14, 2021 | clinicaltrials |
| NCT04699643 | FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 80 | EverNov Medicines (Zhuhai Hengqin) Co., LtdINDUSTRY | 1 | Jan 7, 2021 | clinicaltrials |
| NCT00600275 | A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 57 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT04226066 | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 69 | Tasly Tianjin Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04647838 | Tepotinib in Solid Tumors Harboring MET Alterations | unknown | Phase 2 | 100 | Chungbuk National University HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT00031967 | Melatonin and Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 2 | — | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 22, 2020 | clinicaltrials |
| NCT04588324 | Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02253992 | An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 232 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT04569916 | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors | unknown | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT01588821 | Cabozantinib in Advanced Solid Malignancies | completed | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT02857920 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 45 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00002950 | Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer | completed | Phase 1 / Phase 2 | 25 | Yale UniversityOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT01956669 | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | completed | Phase 2 | 57 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 12, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | withdrawn | Phase 2 | 0 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 12, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT03544723 | Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. | unknown | Phase 2 | 40 | MultiVir, Inc.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT00333502 | Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 62 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02843204 | Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 110 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT03361228 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Incyte CorporationINDUSTRY | 1 | May 21, 2020 | clinicaltrials |
| NCT02265510 | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 83 | Incyte CorporationINDUSTRY | 1 | Apr 17, 2020 | clinicaltrials |
| NCT01019187 | Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy | completed | Phase 2 | 226 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT01781429 | Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 136 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Mar 20, 2020 | clinicaltrials |
| NCT02638428 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | unknown | Phase 2 | 90 | Samsung Medical CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00514215 | Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer | completed | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03168061 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | unknown | Phase 1 / Phase 2 | 150 | NanoCarrier Co., Ltd.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT03160833 | A Study of HMPL-453 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 33 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00582816 | Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04179656 | The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor | unknown | Phase 2 | 100 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02451007 | Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors | completed | Phase 2 | 39 | PharmaMarINDUSTRY | 2 | Nov 19, 2019 | clinicaltrials |
| NCT04151329 | A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor | unknown | Phase 1 / Phase 2 | 72 | Bio-Thera SolutionsINDUSTRY | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04143789 | Evaluation of AP-002 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 61 | Altum Pharmaceuticals INCINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03035591 | ODM-207 in Patients With Advance Solid Tumours(BETIDES) | completed | Phase 1 / Phase 2 | 36 | Orion Corporation, Orion PharmaINDUSTRY | 1 | Oct 15, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01606748 | A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin | completed | Phase 2 | 35 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02950103 | Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients | terminated | Phase 2 | 73 | Secretaria de Estado da SaúdeOTHER_GOV | 1 | Sep 30, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Mar 1, 2021source: clinicaltrials